Frenck R Jr, Thompson A, Yeh SH, London A, Sidhu MS, Patterson S, Gruber WC, Emini EA, Scott DA, Gurtman A; the 3011 Study Group. Pediatr Infect Dis J. 2011 Dec;30(12):1086-1091.

This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally. The results support and strengthen the CDC recommendation that a single supplemental dose of PCV13 should be administered to all children 14 to 59 months of age who have received a complete PCV7 schedule. Cost and cost-effectiveness analyses on this topic are, however, still lacking.